Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013

Diagnostic Microbiology and Infectious Disease

Volumn 82, Issue 1, 2015, Pages 78-84

  Sader, Helio S ^a   Farrell, David J ^a   Mendes, Rodrigo E ^a   Flamm, Robert K ^a   Castanheira, Mariana ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

Cephalosporin; MRSA; Staphylococcus aureus; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; AZTREONAM; CEFTAROLINE; CEFTAZIDIME; CEFTRIAXONE; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; ERYTHROMYCIN; EXTENDED SPECTRUM BETA LACTAMASE; LEVOFLOXACIN; LINEZOLID; MEROPENEM; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; BROTH DILUTION; COMMUNITY ACQUIRED INFECTION; CONTROLLED STUDY; DRUG POTENCY; DRUG SENSITIVITY; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; IN VITRO STUDY; KLEBSIELLA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PHENOTYPE; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SKIN INFECTION; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; BACTERIAL SKIN DISEASE; BACTERIUM; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ANTI-BACTERIAL AGENTS; BACTERIA; CEPHALOSPORINS; MICROBIAL SENSITIVITY TESTS; RESPIRATORY TRACT INFECTIONS; SKIN DISEASES, BACTERIAL; UNITED STATES;

EID: 84928375376     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2015.01.015     Document Type: Article

References (18)

1. Clinical and Laboratory Standards Institute (CLSI) M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: ninth edition 2012, CLSI, Wayne, PA.
2. Clinical and Laboratory Standards Institute (CLSI) M100-S24. Performance standards for antimicrobial susceptibility testing: 24th informational supplement 2014, CLSI, Wayne, PA.
3. Critchley I.A., Eckburg P.B., Jandourek A., Biek D., Friedland H.D., Thye D.A. Review of ceftaroline fosamil microbiology: integrated FOCUS studies. J Antimicrob Chemother 2011, 66(Suppl. 3):iii45-iii51.
4. Dryden M.S. Complicated skin and soft tissue infection. J Antimicrob Chemother 2010, 65(Suppl. 3):iii35-iii44.
5. File T.M. Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia. Clin Microbiol Infect 2006, 12(Suppl. 3):31-41.
6. File T.M., Marrie T.J. Burden of community-acquired pneumonia in North American adults. Postgrad Med 2010, 122:130-141.
7. Flamm R.K., Sader H.S., Farrell D.J., Jones R.N. Antimicrobial activity of ceftaroline tested against drug resistant subsets of Streptococcus pneumoniae from United States medical centers. Antimicrob Agents Chemother 2014, 58:2468-2471.
8. Flamm R.K., Sader H.S., Jones R.N. Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE Program, 2009-2011. Diagn Microbiol Infect Dis 2014, 78:437-442.
9. Frampton J.E. Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia. Drugs 2013, 73:1067-1094.
10. Jones R.N., Farrell D.J., Mendes R.E., Sader H.S. Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study. J Antimicrob Chemother 2011, 66(Suppl. 3):iii69-iii80.
11. Karlowsky J.A., Adam H.J., Baxter M.R., Lagace-Wiens P.R., Walkty A.J., Hoban D.J., et al. In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study. Antimicrob Agents Chemother 2013, 57:5600-5611.
12. Kollef M.H., Shorr A., Tabak Y.P., Gupta V., Liu L.Z., Johannes R.S. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005, 128:3854-3862.
13. Lodise T.P., Low D.E. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Drugs 2012, 72:1473-1493.
14. Pfaller M.A., Farrell D.J., Sader H.S., Jones R.N. AWARE ceftaroline surveillance program (2008-2010); trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. Clin Infect Dis 2012, 55(Suppl. 3):S187-S193.
15. Pfaller M.A., Flamm R.K., Sader H.S., Jones R.N. Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011). Diagn Microbiol Infect Dis 2014, 78:422-428.
16. Stevens D.L., Bisno A.L., Chambers H.F., Everett E.D., Dellinger P., Goldstein E.J., et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005, 41:1373-1406.
17. Teflaro™ Package Insert 2012. New York City, NY. Available at . Accessed August 2013. http://www.frx.com/pi/Teflaro_pi.pdf.
18. Tygacil® Package Insert 2012. Wyeth Pharmaceuticals, Philadelphia, PA. Available at . http://www.tygacil.com.